Finland’s TILT raises €22m to progress cancer therapies 07-Feb-2023 By Jane Byrne TILT Biotherapeutics, a Finnish company developing cancer immunotherapies, reported the final close of its €22m (US$23.8m) round, which was led by Finland’s Lifeline Ventures, an early-stage venture capital firm.